Seminars in arthritis and rheumatism最新文献

{"title":"Initiation of glucocorticoids before entering rheumatology care associates with long-term glucocorticoid use in older adults with early rheumatoid arthritis: A joint analysis of Medicare and the Rheumatology Informatics System for Effectiveness (RISE) data","authors":"Andriko Palmowski ,&nbsp;Eric T Roberts ,&nbsp;Jing Li ,&nbsp;Emma Kersey ,&nbsp;Rachael Stovall ,&nbsp;Frank Buttgereit ,&nbsp;Jinoos Yazdany ,&nbsp;Gabriela Schmajuk","doi":"10.1016/j.semarthrit.2024.152535","DOIUrl":"10.1016/j.semarthrit.2024.152535","url":null,"abstract":"<div><h3>Objective</h3><p>To assess relationships between the timing of glucocorticoid (GC) initiation, entrance into rheumatology care, and the duration of GC use in older adults with early rheumatoid arthritis (eRA) in the U.S.</p></div><div><h3>Methods</h3><p>Data from the Rheumatology Informatics System for Effectiveness (RISE) registry and Medicare (2016–2018) were linked. Patients with ≥2 RA ICD codes in RISE were included; the first being the index date which signaled entrance into rheumatology care. GC initiation (between 3 months before to 6 months after the index date) and continuous GC use up to 12 months after the index date were captured using Medicare claims. Cox proportional hazards models with adjustment for confounders assessed differences in the duration of GC use for patients initiating GCs before versus after the index date. Average daily GC doses were estimated.</p></div><div><h3>Results</h3><p>1,733 patients (67 % female; mean age 76 ± 6 years) were included. 41 % initiated GCs, on average 16 ± 58 days before entering rheumatologic care. The mean duration of GC use was 157 days (95 %-CI 143 to 170). GC initiation before rheumatologic care was associated with longer GC use, even after adjustment for confounders (hazard ratio 0.61; 95 %-CI [0.51 to 0.74]). For patients using GCs for ≥3 months, average daily GC doses were &lt;5 mg/d prednisone equivalent.</p></div><div><h3>Conclusion</h3><p>GCs are regularly used in eRA and most often initiated before patients enter rheumatology care. Long-term, low-dose GC use is common and associated with initiation before rheumatology care. Earlier referral to rheumatology might reduce GC exposure among U.S. patients with eRA.</p></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"68 ","pages":"Article 152535"},"PeriodicalIF":4.6,"publicationDate":"2024-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0049017224001756/pdfft?md5=560a31dbb2a8bef8ee537339ed3cc063&pid=1-s2.0-S0049017224001756-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142049328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The control group matters: Pain, physical function and strength improvements relative to the comparator intervention in knee and hip osteoarthritis","authors":"Kendal A. Marriott ,&nbsp;Michelle Hall ,&nbsp;Jacquelyn M. Maciukiewicz ,&nbsp;Rachel D. Almaw ,&nbsp;Emily G. Wiebenga ,&nbsp;Natasha K. Ivanochko ,&nbsp;Daniel Rinaldi ,&nbsp;Emma V. Tung ,&nbsp;Kim L. Bennell ,&nbsp;Monica R. Maly","doi":"10.1016/j.semarthrit.2024.152538","DOIUrl":"10.1016/j.semarthrit.2024.152538","url":null,"abstract":"<div><h3>Background</h3><p>In knee and hip osteoarthritis (OA), the mechanism for resistance exercise improving clinical outcomes and the dose-response between strength and clinical outcomes are unknown; in part due to inconsistent trial designs across studies.</p></div><div><h3>Purpose</h3><p>To determine whether the effects of resistance exercise interventions on pain and function differ based on comparator group; and whether there is an association between improvements in lower extremity strength with improvements in pain and function in knee and hip OA.</p></div><div><h3>Methods</h3><p>We searched 6 databases (inception to January 28 2023,) for randomized controlled trials (RCTs) comparing land-based, resistance exercise-only interventions with no intervention or any other intervention. There were four subgroups for comparator intervention: NONE (none/placebo/sham/usual care), EXE (other exercise interventions alone), NONEXE (non-exercise interventions alone), COMBO (combined exercise + non-exercise interventions). The between-group effect (ES) was calculated for immediate post-intervention pain and function (activities of daily living (ADL) and sports/recreation (SPORT)). Meta-regression analyses were completed to evaluate the association between improvements in lower extremity strength (independent variable) and improvements in pain, ADL and SPORT (dependent variables), irrespective of comparator intervention.</p></div><div><h3>Results</h3><p>For knee OA (257 studies), there were large benefits for pain [ES (95 % CI) = -0.92 (-1.15, -0.69)], ADL [-0.79 (-1.01, -0.56)] and SPORT [-0.79 (-1.02, -0.56)] favouring resistance exercise interventions compared to NONE. For knee pain, there was also a moderate benefit favouring COMBO interventions compared to resistance exercise interventions [0.44 (0.23, 0.65)]. For hip OA (15 studies), there were moderate benefits for pain [-0.51 (-0.68, -0.33)], ADL [-0.57 (-0.78, -0.36)] and SPORT [-0.52 (-0.70, -0.35)] favouring exercise interventions compared to NONE. For hip pain, there was also a moderate benefit favouring NONEXE interventions compared to resistance exercise interventions [0.57 (0.17, 0.97)]. For knee OA, greater strength gains were associated with larger improvements in pain [β (95 % CI) = -0.24 (-0.38, -0.09)], ADL [-0.43 (-0.73, -0.12)] and SPORT [-0.37 (-0.73, -0.00)].</p></div><div><h3>Conclusion</h3><p>In knee and hip OA, the effects of resistance exercise on pain and function improvements depend on the comparator intervention. For knee OA, a dose-response relationship was observed between lower extremity strength gains with pain and function improvements.</p></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"68 ","pages":"Article 152538"},"PeriodicalIF":4.6,"publicationDate":"2024-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0049017224001781/pdfft?md5=b213f890a73d859c14d35883761f06a9&pid=1-s2.0-S0049017224001781-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142098144","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of a handheld ultrasound device with cart-based ultrasound for the assessment of gout lesions in people with established gout","authors":"Rachel Murdoch ,&nbsp;Lene Terslev ,&nbsp;Julia Martin ,&nbsp;Borislav Mihov ,&nbsp;Gregory D Gamble ,&nbsp;Søren Torp-Pedersen ,&nbsp;Anne M Horne ,&nbsp;Nicola Dalbeth","doi":"10.1016/j.semarthrit.2024.152533","DOIUrl":"10.1016/j.semarthrit.2024.152533","url":null,"abstract":"<div><h3>Objectives</h3><p>Use of handheld portable ultrasound is increasing and would improve access for people with rheumatic disease when conventional, cart-based ultrasound is unavailable. This study compared handheld and cart-based ultrasound for the assessment of gout lesions in people with gout.</p></div><div><h3>Methods</h3><p>The lower limbs of 21 participants with gout were independently scanned at six sites (1st and 2nd metatarsophalangeal joints, knee, patellar ligament, Achilles tendon, and peroneal tendons) using cart-based (LOGIQ P9) and handheld (Vscan Air™) ultrasound by two rheumatologists. One rheumatologist was randomized to scan the right or left leg first with the cart-based or handheld ultrasound. The other rheumatologist scanned the legs in the opposite order with the imaging devices reversed. Images were saved and blinded images scored for double contour, tophus, erosion and aggregates using OMERACT definitions by two rheumatologists experienced in gout ultrasound.</p></div><div><h3>Results</h3><p>On handheld ultrasound, 90% of participants had at least one site with double contour, tophus and erosions, and 100% had at least one site with aggregates. There were similar findings using cart-based ultrasound. However, site-level inter-device analysis showed only fair-good agreement: kappa (percentage agreement) for double contour 0.22 (67%), tophus 0.46 (77%), erosion 0.63 (83%) and aggregates 0.37 (75%). There were more aggregates detected by cart-based ultrasound in joints and more tophi detected by handheld ultrasound in ligaments and tendons.</p></div><div><h3>Conclusions</h3><p>Handheld ultrasound can detect gout lesions in people with established gout. However, concordance between cart-based and handheld ultrasound in detection of some gout lesions is low, particularly double contour and aggregates.</p></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"68 ","pages":"Article 152533"},"PeriodicalIF":4.6,"publicationDate":"2024-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0049017224001732/pdfft?md5=4eb28523b0dd53a5cbcc22b8cd439b41&pid=1-s2.0-S0049017224001732-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142021343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interplay between polygenic risk score and solar insolation: Implication for systemic lupus erythematosus diagnosis and pathogenesis","authors":"I-Chieh Chen ,&nbsp;Ta-Chien Chan ,&nbsp;Hui-Wen Yang ,&nbsp;Yen-Ju Chen ,&nbsp;Yi-Ming Chen","doi":"10.1016/j.semarthrit.2024.152531","DOIUrl":"10.1016/j.semarthrit.2024.152531","url":null,"abstract":"<div><h3>Objectives</h3><p>This research elucidates the correlation between solar radiation insolation, polygenic risk score (PRS), and systemic lupus erythematosus (SLE) diagnosis, utilizing genomic, environmental, and clinical data.</p></div><div><h3>Methods</h3><p>We included 1,800 SLE participants and 1,800 controls from the Taiwan Precision Medicine Initiative, genotyped via the Affymetrix Genome-Wide TWB 2.0 SNP Array. The study employed a SLE-PRS tailored for individuals of Taiwanese ancestry, comprising 27 single nucleotide polymorphisms (SNPs). QGIS computed solar radiation insolation from participants' residences. We employed logistic regression to investigate the associations between SLE-PRS, solar insolation susceptibility, and SLE. Additive and multiplicative interactions were utilized to assess the interactions between solar insolation and SLE-PRS regarding the risk of SLE.</p></div><div><h3>Results</h3><p>SLE patients showed decreased solar insolation (<em>p</em> &lt; 0.001). The highest decile of SLE-PRS exhibited a statistically significant lower solar insolation 1, 3, 6, and 12 months prior to diagnosis as compared to the lowest decile. Specifically, there were significant differences observed at 1 and 12 months (<em>p</em> = 0.025 and <em>p</em> = 0.004, respectively). It suggests that higher SLE-PRS correlated with reduced solar insolation tolerance. We observed an increase in SLE risk across ascending SLE-PRS percentiles exclusively in the high solar insolation group, not in the low solar insolation group. However, the interaction effect of SLE-PRS and solar insolation on SLE risk is not statistically significant. Compared to the lowest decile, the highest SLE-PRS decile showed a 10.98-fold increase in SLE risk (95 % CI, 3.773–31.952, <em>p</em> &lt; 0.001). High SLE-PRS scores in conjunction with high solar insolation contribute to SLE incidence.</p></div><div><h3>Conclusions</h3><p>Our study unveils the intertwined nature of UV insolation and polygenic risks in SLE. Future studies should explore the preventative potential of robust solar radiation protection for high-risk individuals before the disease onset.</p></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"68 ","pages":"Article 152531"},"PeriodicalIF":4.6,"publicationDate":"2024-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141998547","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical stratification of 1318 Primary Sjögren's Syndrome patients","authors":"Jinxia Fang ,&nbsp;Jiajia Wang ,&nbsp;Jing Luo ,&nbsp;Ping Wang ,&nbsp;Jin Zhang ,&nbsp;Dan Chen ,&nbsp;Wenjing Ye ,&nbsp;Yi Zhang ,&nbsp;Shaobiao Pan ,&nbsp;Xiaobing Wang","doi":"10.1016/j.semarthrit.2024.152537","DOIUrl":"10.1016/j.semarthrit.2024.152537","url":null,"abstract":"<div><h3>Objective</h3><p>Primary Sjögren's Syndrome (pSS) is a complex autoimmune disorder characterized by diverse clinical manifestations yet lacking effective therapeutic strategies currently. This study aims to gain a thorough understanding of the clinical landscape of pSS and further delineate its clinical subtypes, thereby enabling the efficient management for pSS.</p></div><div><h3>Methods</h3><p>We conducted a cross-sectional observational study of 1318 pSS patients. The pSS patients were categorized and compared based on gender, anti-SSA antibodies, and labial salivary gland biopsies (LGSB). Unsupervised clustering analysis was employed to identify pSS subtypes using systemic involvement among patients. Furthermore, we assessed clinical and biological variances among these subtypes.</p></div><div><h3>Results</h3><p>Through group comparisons, we observed more pronounced extraglandular manifestations among male patients, SSA-negative group, and those with positive LGSB results. Based on systemic involvement, pSS patients were categorized into four groups. C1 exhibited minimal systemic involvement, lacking hematologic or serologic manifestations, with the lowest ESSDAI scores. C2 presented with serologic changes in all patients, partial joint involvement, and no hematologic systemic manifestations. C3 lacked joint involvement but all members displayed hematologic systemic involvement, with higher rates of renal, cutaneous, and systemic manifestations. C4 encompassed patients with joint and hematologic involvement, displaying the highest ESSDAI scores. The positivity rates of antibodies, immunological parameters, and inflammatory markers exhibited significant differences among the groups. Furthermore, notable variances were observed in the expression of peripheral blood transcriptomic modules among these groups.</p></div><div><h3>Conclusion</h3><p>In this cohort study, we summarized the clinical characteristics of Chinese patients with pSS and identified four distinct subgroups of pSS based on systemic involvement, revealing clinical and molecular disparities that unveil distinct pathobiological endotypes. Our findings hold significant implications for clinical management.</p></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"68 ","pages":"Article 152537"},"PeriodicalIF":4.6,"publicationDate":"2024-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141985636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical characteristics of idiopathic inflammatory myopathies patients with anti-PM/Scl antibodies","authors":"Longyang Zhu ,&nbsp;Chen Zong ,&nbsp;Yiran Chen ,&nbsp;Guochun Wang ,&nbsp;Yongpeng Ge","doi":"10.1016/j.semarthrit.2024.152536","DOIUrl":"10.1016/j.semarthrit.2024.152536","url":null,"abstract":"<div><h3>Objectives</h3><p>To analyze the clinical features of idiopathic inflammatory myopathies (IIMs) patients with anti-PM/Scl antibodies.</p></div><div><h3>Methods</h3><p>In this retrospective cohort study, we compared the clinical manifestations between patients who were solely positive for anti-PM/Scl antibodies (isolated anti-PM/Scl group) and those with a coexistence of anti-PM/Scl antibodies and myositis-specific antibodies (MSAs) (double-positive group).</p></div><div><h3>Results</h3><p>Sixty-five IIMs patients positive for anti-PM/Scl antibodies were included, among whom 51 (78.5 %) were females, with a mean age of 49.1 years. Thirty-four (52.3 %) patients coexisted with MSAs. Compared to the double-positive group, the isolated anti-PM/Scl group demonstrated a higher proportion of women (90.3 % vs 67.6 %, <em>p</em> = 0.026) and a higher incidence of sclerodactyly (16.1 % vs 0, <em>p</em> = 0.021). Although there were no differences in the incidence of muscular weakness, dysphagia, or creatine kinase levels, thigh magnetic resonance imaging (MRI) revealed less muscle edema, atrophy, and fatty replacement in the isolated anti-PM/Scl group (<em>p</em> &lt; 0.05). Interstitial lung disease (ILD) occurred in 80 % of patients, more frequently in the double-positive group (90.6 % vs 67.9 %, <em>p</em> = 0.028). According to HRCT, non-specific interstitial pneumonia (NSIP) was the most common pattern among anti-PM/Scl antibodies positive IIMs patients. The double-positive group exhibited higher ferritin levels, and a lower peripheral lymphocyte count (<em>p</em> &lt; 0.05). The mortality rate in the double-positive group was higher than that in the isolated anti-PM/Scl group (20.6 % vs 0, <em>p</em> = 0.034).</p></div><div><h3>Conclusion</h3><p>Among IIMs patients who tested positive for anti-PM/Scl antibodies, ILD emerged as the predominant clinical feature, particularly when combined with MSA. Notably, patients with isolated anti-PM/Scl antibodies exhibited a favorable prognosis following immunotherapy.</p></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"68 ","pages":"Article 152536"},"PeriodicalIF":4.6,"publicationDate":"2024-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0049017224001768/pdfft?md5=c2c57c33f28ded5ead1d6877826f47dc&pid=1-s2.0-S0049017224001768-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142047087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bone and entheseal targets for growth factors in diffuse idiopathic skeletal hyperostosis","authors":"Geoffrey Owen Littlejohn","doi":"10.1016/j.semarthrit.2024.152532","DOIUrl":"10.1016/j.semarthrit.2024.152532","url":null,"abstract":"<div><h3>Introduction</h3><p>Diffuse idiopathic skeletal hyperostosis (DISH) is a common condition of the adult skeleton where new bone growth occurs in entheseal and bony regions. The cause for the new bone growth is unclear but many lines of evidence point to a role for growth factors linked to abnormal metabolism in these patients. The bone targets for these presumed growth factors are poorly defined. This review summarises the clinical evidence relevant to the sites of origin of new bone formation in DISH to better define potential cellular targets for bone growth in DISH.</p></div><div><h3>Methods</h3><p>This is a narrative review of relevant papers identified from searches of PubMed and online journals.</p></div><div><h3>Results</h3><p>Sites of new bone growth in the enthesis were identified in patients with DISH, with likely cellular targets for growth factors being mesenchymal stem cells in the outer part of the enthesis. Similar undifferentiated skeletal stem cells are present in the outer annulus fibrosis and in the bony eminences of vertebral bodies and other bones, with the potential for response to growth factors.</p></div><div><h3>Conclusion</h3><p>Mesenchymal stem cells are present in specific entheseal and bony locations that are likely responsive to putative growth factors leading to new bone formation characteristic of DISH. Further study of these regions in the context of metabolic abnormalities in DISH will allow for better understanding of the pathophysiology of this common condition.</p></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"68 ","pages":"Article 152532"},"PeriodicalIF":4.6,"publicationDate":"2024-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0049017224001720/pdfft?md5=3aa4eb3edb994d300d40191174489171&pid=1-s2.0-S0049017224001720-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141985665","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Construct validity of PROMIS pain interference, fatigue, and physical function as patient-reported outcomes in adults with idiopathic inflammatory myopathies: An international study from the OMERACT myositis working group","authors":"Ellen Romich ,&nbsp;Didem Saygin ,&nbsp;Dana DiRenzo ,&nbsp;Christopher A. Mecoli ,&nbsp;Ingrid de Groot ,&nbsp;Karin Lodin ,&nbsp;Malin Regardt ,&nbsp;Catherine Sarver ,&nbsp;Ju Yeon Kim ,&nbsp;Jin Kyun Park ,&nbsp;Kelly Beer ,&nbsp;Merrilee Needham ,&nbsp;Helene Alexanderson ,&nbsp;Lisa Christopher-Stine ,&nbsp;Marianne de Visser ,&nbsp;Joost Raaphorst ,&nbsp;OMERACT Myositis Working Group","doi":"10.1016/j.semarthrit.2024.152534","DOIUrl":"10.1016/j.semarthrit.2024.152534","url":null,"abstract":"<div><h3>Background</h3><p>Validated patient-reported outcome measures to assess disease impact in patients with adult idiopathic inflammatory myopathies (IIMs) are needed. The objective of this study was to assess the construct validity of PROMIS Pain Interference, Fatigue, and Physical Function measures in comparison with core disease activity measures.</p></div><div><h3>Methods</h3><p>Adults with IIM, excluding inclusion body myositis, from OMERACT Myositis Working Group (MWG) clinic sites completed PROMIS Short Form v1.0—Pain Interference 6a, PROMIS Short Form v1.0—Fatigue 7a, and PROMIS Short Form v2.0—Physical Function 8b measures. Core disease activity measures including patient and physician global disease activity assessments, manual muscle testing, serum creatine kinase activity, and Health Assessment Questionnaire Disability Index (HAQ-DI) were simultaneously assessed. To evaluate construct validity, a priori hypotheses for the expected correlations between PROMIS measures, age, and core disease measures were determined by &gt;70 % agreement among MWG members and were compared against observed Pearson's correlations. Internal consistency of items and floor or ceiling effects for the PROMIS measures were also assessed. Subgroup analysis according to IIM subtype (dermatomyositis vs. non-dermatomyositis IIM) was performed.</p></div><div><h3>Results</h3><p>135 adults with IIM from 5 countries across North America, Europe, Asia, and Australia were included. For construct validity, a priori hypotheses were confirmed for 5 of 6 (83 %) PROMIS Pain Interference, 4 of 5 (80 %) PROMIS Fatigue, and 3 of 4 (75 %) PROMIS Physical Function correlations. Internal consistency was high for each PROMIS measure (Cronbach's alpha &gt;0.9). Ceiling effects were observed only for PROMIS Pain Interference, with low/no pain in 29 % of patients. Subgroup analysis between dermatomyositis (<em>n</em> = 65) and non-dermatomyositis (<em>n</em> = 70) subtypes demonstrated similar correlations between PROMIS measures and disease activity measures.</p></div><div><h3>Conclusions</h3><p>PROMIS Short Form v1.0—Pain Interference 6a, PROMIS Short Form v1.0—Fatigue 7a, and PROMIS Short Form v2.0—Physical Function 8b measures demonstrate strong construct validity when compared to core disease activity measures in IIM, with consistent results across IIM subtypes. These findings support the use of these selected PROMIS measures to assess core domains of interest for measuring life impact in IIMs.</p></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"68 ","pages":"Article 152534"},"PeriodicalIF":4.6,"publicationDate":"2024-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142001996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient questionnaires for clinical decisions at the point of care, in addition to research reports, an intellectual and ethical opportunity for rheumatologists: A tribute to Frederick Wolfe, MD (July 1, 1936 - September 5, 2023)","authors":"Theodore Pincus ,&nbsp;Leigh F. Callahan","doi":"10.1016/j.semarthrit.2024.152528","DOIUrl":"10.1016/j.semarthrit.2024.152528","url":null,"abstract":"","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"69 ","pages":"Article 152528"},"PeriodicalIF":4.6,"publicationDate":"2024-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142381619","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differences in the autoantibody phenotypes and long-term outcomes between juvenile- and adult-idiopathic inflammatory myopathies","authors":"Hideaki Tsuji ,&nbsp;Ran Nakashima ,&nbsp;Takahiro Yasumi ,&nbsp;Tsuneo Sasai ,&nbsp;Yuki Ichimura ,&nbsp;Mirei Shirakashi ,&nbsp;Hideo Onizawa ,&nbsp;Ryosuke Hiwa ,&nbsp;Koji Kitagori ,&nbsp;Shuji Akizuki ,&nbsp;Akira Onishi ,&nbsp;Hajime Yoshifuji ,&nbsp;Masao Tanaka ,&nbsp;Naoko Okiyama ,&nbsp;Tsuneyo Mimori ,&nbsp;Akio Morinobu","doi":"10.1016/j.semarthrit.2024.152530","DOIUrl":"10.1016/j.semarthrit.2024.152530","url":null,"abstract":"<div><h3>Objective</h3><p>To investigate differences in autoantibodies, clinical features, and long-term outcomes between juvenile-idiopathic inflammatory myopathy (IIM) and adult-IIM</p></div><div><h3>Methods</h3><p>Autoantibodies, clinical characteristics, and drug-free conditions for a maximum of 20 years were retrospectively analyzed in 320 Japanese IIM patients (juvenile-IIM, <em>n</em> = 34; adult-IIM, <em>n</em> = 286) using the Kyoto University Registry.</p></div><div><h3>Results</h3><p>Autoantibodies observed in juvenile-IIM were anti-TIF1-γ (15 %), anti-MDA-5 (15 %), anti-ARS (9 %), and anti-NXP-2 (6 %). Those observed in adult-IIM were anti-ARS (32 %), anti-MDA-5 (23 %), anti-TIF1-γ (8 %), anti-SRP (8 %), anti-Mi-2 (2 %), and anti-NXP-2 (1 %). The cumulative drug-free condition rate was higher in juvenile-IIM than in adult-IIM up to 20 years (juvenile-IIM vs. adult-IIM, 34 % vs. 18 %, <em>p</em> = 0.0016). Anti-TIF1-γ was associated with lesser muscle symptoms (60 % vs. 90 %), malignancy (0 % vs. 57 %), and glucocorticoid use (40 % vs. 86 %) in juvenile-IIM compared to adult-IIM, while juvenile-IIM more achieved drug-free conditions (60 % vs. 25 %). Both juvenile-IIM and adult-IIM with anti-MDA-5 demonstrated a high frequency of amyopathic dermatomyositis, interstitial lung disease (ILD), and multi-immunosuppressive therapy, with high drug-free conditions (50 % vs. 49 %). Both juvenile-IIM and adult-IIM with anti-ARS showed frequent skin rashes, muscle symptoms, and ILD, frequent need for multi-immunosuppressive therapy, and low drug-free condition rates (0 % vs. 3 %). Both juvenile-IIM and adult-IIM with anti-NXP-2 showed frequent skin rashes and muscle symptoms, low ILD frequency, and frequent use of methotrexate and glucocorticoids, which did not achieve drug-free conditions (0 % vs. 0 %).</p></div><div><h3>Conclusions</h3><p>Drug-free condition was achieved more frequently in juvenile-IIM patients than adult-IIM patients. Specific autoantibodies were associated with different clinical characteristics and outcomes between juvenile-IIM and adult-IIM.</p></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"68 ","pages":"Article 152530"},"PeriodicalIF":4.6,"publicationDate":"2024-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141978861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}